What's Happening?
KalVista Pharmaceuticals, Inc. has announced preliminary revenue results for the fourth quarter and full year of 2025, highlighting the successful launch of EKTERLY, a novel plasma kallikrein inhibitor for hereditary angioedema (HAE). The company reported approximately $35 million in revenue for the fourth quarter and $49 million for the full year. Since its U.S. launch in July 2025, EKTERLY has seen rapid adoption, with 1,318 patient start forms and 580 unique prescribers activated by the end of the year. The drug is the first oral on-demand treatment for HAE, offering a non-injection alternative. KalVista has also partnered with Multicare Pharmaceuticals to commercialize sebetralstat in Latin America, expanding its market reach.
Why It's Important?
The successful
launch of EKTERLY represents a significant advancement in the treatment of hereditary angioedema, providing patients with a more convenient oral option. This development could potentially shift the standard of care for HAE, reducing the burden of injections for patients. The strong revenue performance underscores the market demand for innovative treatments and positions KalVista as a key player in the HAE treatment landscape. The expansion into international markets, including a planned regulatory filing for pediatric use, indicates a strategic growth trajectory that could enhance global access to this therapy.
What's Next?
KalVista plans to file a new drug application in the U.S. for pediatric use of EKTERLY in 2026, with a launch anticipated in 2027. The company is also preparing to expand into additional global markets, leveraging its partnerships to increase accessibility. Continued growth in patient refills suggests sustained demand, and KalVista aims to maintain this momentum by ensuring reliable access and operational excellence. The company's strategic focus on expanding its market presence and product offerings could further solidify its position in the pharmaceutical industry.
